Derek J. McPhee

At the request of the authors of this paper [1], we wish to announce the following corrections:

After a five year hiatus, we are pleased to announce the resumption of publication of the MDPI journal Pharmaceuticals (ISSN 1424-8247). First launched in 2004, few suitable papers were submitted and only one was published [1], before our limited editorial resources at the time led us to temporarily discontinue publication. Several things have changed since then. First, there has been an explosive growth in the number of manuscripts submitted and published in MDPI’s various current journals [2], whose topics clearly fall within the intended scope of Pharmaceuticals and we feel that these manuscripts merit a dedicated forum. Second, the expansion of MDPI, now with Editorial Offices and staff in Basel (Switzerland) and Beijing (China), allows us to provide Pharmaceuticals’ authors with all the services they could desire and deserve: a simple manuscript submission process, rigorous peer review, quick revision turnaround, Open Access publication on a new and attractive platform and coverage by all the major abstracting services. In addition, a new Editorial Board comprised of noted academic and industry scientists has been set up for Pharmaceuticals. Finally, to better focus the subject matter published in Pharmaceuticals on molecular medicines, we have also set up a special section in International Journal of Molecular Sciences (IJMS, ISSN 1422-0067) for papers on nutraceuticals or chemopreventives. We look forward to receiving and publishing your papers and as always, we welcome your comments and suggestions.

As has now become a custom for Molecules, as one year ends and another starts its Publisher and Editor-in-Chief would like to take stock of our progress in 2008 and offer our readership a preview of things to come in 2009. Just as we had hoped in last year’s editorial [1], the year that just concluded proved to be another outstanding one for MDPI's flagship journal Molecules. By year’s end we had published 239 papers and three Editorials or Editor's Notes for a total of 3,252 pages. While the 8% growth in the number of papers published compared to 2007 may appear modest, the number of pages published represented a 22% increase over the prior year, and was largely attributable to the increase in the number of reviews published.

Effective immediately authors and readers shall notice some minor yet significant changes to the papers published in this and other MDPI journals [1].

As already anticipated in August 2007 [1], the year that just concluded proved to be a truly outstanding one for MDPI's flagship journal Molecules.

After a three year interruption, we have decided to resume publication of the MDPI journal Pharmaceuticals (ISSN 1424-8247). This journal will henceforth publish papers on typical molecular medicines. In order to provide publishing services for those papers about topics which can be categorized as nutraceuticals or chemopreventives, we have set up a section in International Journal of Molecular Sciences (ISSN 1422-0067, IJMS) at http://www.mdpi.org/ijms/sections/nc.htm. Under this model we consider that the first paper [1] published in Pharmaceuticals (ISSN 1424-8247) should rightly have been treated as a paper for the nutraceuticals or chemopreventives section of IJMS.

It has been brought to our attention by an alert medicinal chemist from the P. R. China that Scheme 3 and the Experimental section of this paper [1] had been copied from an earlier paper by Gong et al. [2], published in Chinese [3].